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Abstract
Background: Research	into	drug	hypersensitivity	associated	with	the	expression	of	
specific	HLA	alleles	has	 focussed	on	 the	 interaction	between	parent	drug	and	 the	
HLA	with	no	attention	given	to	reactive	metabolites.	For	this	reason,	we	have	studied	
HLA‐B*13:01‐linked	dapsone	hypersensitivity	to	(a)	explore	whether	the	parent	drug	
and/or	nitroso	metabolite	activate	T	cells	and	(b)	determine	whether	HLA‐B*13:01	is	
involved	in	the	response.
Methods: Peripheral	blood	mononuclear	cells	(PBMC)	from	six	patients	were	cultured	
with	 dapsone	 and	 nitroso	 dapsone,	 and	 proliferative	 responses	 and	 IFN‐γ	 release	
were	measured.	Dapsone‐	and	nitroso	dapsone‐specific	T‐cell	clones	were	generated	
and	 phenotype,	 function,	 HLA	 allele	 restriction,	 and	 cross‐reactivity	 assessed.	
Dapsone	intermediates	were	characterized	by	mass	spectrometry.
Results: Peripheral	blood	mononuclear	cells	from	six	patients	and	cloned	T	cells	pro‐
liferated	 and	 secreted	Th1/2/22	 cytokines	when	 stimulated	with	dapsone	 (clones:	
n	=	395;	 80%	CD4+	 CXCR3hiCCR4hi,	 20%	CD8+CXCR3hiCCR4hiCCR6hiCCR9hiCCR1
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1  | INTRODUC TION
Genome‐wide	association	studies	have	 identified	strong	associ‐
ations	between	the	expression	of	HLA	alleles	and	susceptibility	
to	drug	hypersensitivity.1	These	data	suggest	that	drugs	bind	se‐
lectively	 to	 the	HLA	protein	 to	 activate	 the	T	 cells	 that	 partic‐
ipate	 in	 the	 adverse	 event.	 Molecular	 docking	 studies	 support	
this	 concept2,3;	 however,	modeling	 data	 have	 to	 be	 interpreted	
with	 caution	as	 the	nature	of	 the	drug‐HLA	protein	 interaction	
and	the	requirement	for	a	specific	peptide	in	the	binding	groove	
has	not	been	determined.	The	most	robust	genetic	associations	
are	 between	 HLA	 class	 I	 alleles	 and	 abacavir	 hypersensitiv‐
ity,4	 flucloxacillin	 liver	 injury	 (both	 HLA‐B*57:01),5	 carbamaze‐
pine‐induced	 Stevens	 Johnson	 syndrome	 (HLA‐B*15:02),6 and 
allopurinol	 hypersensitivity	 (HLA‐B*58:01),7	 and	 in	 each	 case,	
mechanistic	studies	have	shown	that	CD8+	T	cells	are	activated	
when	 the	 drug	 interacts	 with	 the	 relevant	 HLA	 protein.7,8	 For	
abacavir	 and	 carbamazepine,	 the	 drug	HLA	binding	 site	 is	 very	
different;	abacavir	binds	deep	in	the	HLA	peptide	binding	pocket,	
while	carbamazepine	binds	to	a	site	closer	to	the	T‐cell	receptor	
interface.	Despite	this,	both	drugs	interact	with	HLA	proteins	via	
a	reversible	interaction	to	stimulate	T	cells.	T	cells	from	patients	
with	allopurinol	hypersensitivity	are	activated	with	a	stable	me‐
tabolite,	 oxypurinol,	 also	 via	 a	 direct	 binding	 interaction	 with	
HLA.	In	contrast,	flucloxacillin‐specific	T	cells	from	patients	with	
liver	 injury	 are	 activated	with	 drug‐protein	 adducts,	 via	 a	 hap‐
ten	mechanism	involving	the	spontaneous	binding	of	the	drug	to	
protein	 and	 antigen	 processing.	 This	 brief	 discussion	 illustrates	
that	 rapid	progress	has	been	made	 in	our	understanding	of	 the	
relationship	between	drug	HLA	binding	and	 the	activation	of	T	
cells;	 however,	 reactive	 drug	metabolites	 have	 been	 ignored	 in	
the	study	of	HLA	allele‐restricted	forms	of	drug	hypersensitivity.	
This	is	primarily	because	of	the	absence	of	synthetic	reactive	me‐
tabolites	for	functional	studies	with	T	cells	 from	hypersensitive	
patients.
A	reactive	metabolite	of	sulfamethoxazole	is	known	to	activate	
patient	 T	 cells	 via	 a	 hapten	 mechanism12,13;	 however,	 sulfame‐
thoxazole	reactions	are	not	associated	with	a	specific	HLA	allele.	
Thus,	we	recently	synthesized	the	nitroso	metabolite	of	dapsone	
and	 studied	 the	 priming	 of	 naïve	 T	 cells	 from	 healthy	 donors.15 
Dapsone	contains	a	sulfone	group	that	 links	two	aromatic	amine	
moieties.	Oxidative	metabolism	of	 the	amine	groups	generates	a	
hydroxylamine.	 The	 hydroxylamine	 undergoes	 spontaneous	 oxi‐
dation	to	form	nitroso	dapsone,	which	binds	covalently	to	cellular	
proteins.16,17	Naïve	CD4+	 and	CD8+	 T	 cells	 from	healthy	 donors	
are	activated	with	 the	parent	drug	and	nitroso	metabolite	when	
Tregs	were	removed	and	the	compounds	were	presented	by	den‐
dritic	cells.15	These	data	show	that	both	forms	of	the	drug	interact	
with	multiple	HLA	molecules	and	have	the	capacity	to	stimulate	T	
cells	when	regulatory	pathways	have	been	manipulated.
Dapsone	 is	 used	 in	 combination	with	 other	 drugs	 for	 the	 treat‐
ment	of	infectious	diseases	such	as	leprosy	and	malaria.	0.5%‐3.6%	of	
treated	patients	develop	a	hypersensitivity	syndrome	characterized	by	
fever,	skin	rash,	and	internal	organ	involvement	4‐6	weeks	after	treat‐
ment	commences.18	HLA‐B*13:01	is	associated	with	the	development	
of	dapsone	hypersensitivity	in	Chinese	and	Thai	patients,19,20 and mod‐
eling	data	suggest	that	dapsone	may	fit	in	the	peptide	recognition	site	
of	HLA‐B*13:01.21	Dapsone‐treated	cell	lines	expressing	HLA‐B*13:01	
have	been	shown	to	activate	T	cells,	while	peripheral	blood	mononu‐
clear	cells	(PBMC)	from	2/7	patients	secrete	high	levels	of	the	cytolytic	
molecule	granulysin	when	stimulated	with	the	drug.22	Despite	this,	a	
detailed	analysis	of	 the	phenotype	and	function	of	dapsone‐specific	
T	cells	has	not	been	performed.	Moreover,	the	activation	of	patient	T	
cells	with	nitroso	dapsone	has	not	been	investigated.	Thus,	our	study	
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0hi)	and	nitroso	dapsone	(clones:	n	=	399;	78%	CD4+,	22%	CD8+	with	same	chemokine	
receptor	profile).	CD4+	and	CD8+	clones	were	HLA	class	II	and	class	I	restricted,	re‐
spectively,	 and	 displayed	 three	 patterns	 of	 reactivity:	 compound	 specific,	 weakly	
cross‐reactive,	and	strongly	cross‐reactive.	Nitroso	dapsone	formed	dimers	in	culture	
and	was	reduced	to	dapsone,	providing	a	rationale	for	the	cross‐reactivity.	T‐cell	re‐
sponses	to	nitroso	dapsone	were	dependent	on	the	formation	of	a	cysteine‐modified	
protein	adduct,	while	dapsone	interacted	in	a	labile	manner	with	antigen‐presenting	
cells.	CD8+	clones	displayed	an	HLA‐B*13:01‐restricted	pattern	of	activation.
Conclusion: These	studies	describe	the	phenotype	and	function	of	dapsone‐	and	ni‐
troso	 dapsone‐responsive	 CD4+	 and	 CD8+	 T	 cells	 from	 hypersensitive	 patients.	
Discovery	of	HLA‐B*13:01‐restricted	CD8+	T‐cell	responses	indicates	that	drugs	and	
their	reactive	metabolites	participate	in	HLA	allele‐linked	forms	of	hypersensitivity.
K E Y W O R D S
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had	three	primary	objectives:	to	investigate	whether	dapsone	and/or	
nitroso	dapsone	activates	CD4+	and	CD8+	T	cells	from	hypersensitive	
patients,	to	define	phenotype	and	function	of	drug‐specific	T	cells,	and	
to	explore	whether	HLA‐B*13:01	is	directly	involved	in	the	drug‐/drug	
metabolite‐specific	T‐cell	response.
2  | METHODS
2.1 | Human subjects
Venous	blood	(50	mL)	was	collected	from	6	dapsone	hypersensitive	
patients.	Table	1	summarizes	the	demographics	of	the	patients.	Table	
S1	shows	results	of	HLA	typing.	HLA‐B*13:01+	donors	(n	=	4)	with	
no	history	of	dapsone	exposure	and	HLA‐B*13:01+	dapsone‐toler‐
ant	patients	(n	=	4)	were	selected	as	a	control	groups.	Patch	testing	
was	 conducted	on	 the	back	of	 patients	with	 dapsone	 (0.1%‐25%).	
The	patch	was	removed	after	48	hours.	Results	were	recorded	after	
a	 further	 24	hours	 to	 exclude	 any	 false‐positive	 responses	 result‐
ing	 from	 the	 patch	 tape.	 The	 study	 was	 approved	 by	 the	 Ethical	
Committee	 of	 the	 Shandong	 Provincial	 Institute	 of	 Dermatology	
and	 Venereology,	 and	 informed	 written	 consent	 was	 obtained.	 A	
material	transfer	agreement	was	signed	prior	to	shipment	of	PBMC	
to	Liverpool.
2.2 | Lymphocyte transformation test and 
PBMC ELIspot
Peripheral	 blood	 mononuclear	 cells	 (1.5	×	105	cell/well)	 from	 hy‐
persensitive	patients	and	control	donors	were	incubated	with	dap‐
sone	(125‐500	µmol/L),	nitroso	dapsone	(10‐40	µmol/L),	rifampicin	
(10‐100	µmol/L),	 clofazimine	 (10‐100	µmol/L),	 or	 tetanus	 toxoid	
(5 μg/mL,	as	a	positive	control)	in	culture	medium	for	5	days.	[3H]thy‐
midine	was	added	for	the	final	16	hours	of	the	experiment.	 IFN‐γ‐
secreting	PBMC	were	 visualized	using	ELIspot	by	 culturing	PBMC	
(5	×	105 cell/well)	in	medium	with/without	optimal	concentrations	of	
dapsone	or	nitroso	dapsone	for	48	hours.
2.3 | Generation and characterization of drug‐
specific T‐cell clones
Dapsone	and	nitroso	dapsone‐responsive	T‐cell	clones	were	gener‐
ated	from	patients	5,	6,	and	8	by	serial	dilution	and	characterized	in	
G R A P H I C A L  A B S T R A C T
Dapsone	and	nitroso	dapsone	activate	CD4+	and	CD8+	T	cells	from	hypersensitive	patients	via	different	mechanisms.	Dapsone	and	nitroso	
dapsone	interact	with	HLA‐B*13:01	to	activate	certain	CD8+	clones.	Dapsone	hypersensitivity	should	be	used	as	an	example	to	solve	the	
structure	of	drug	metabolite‐modified	peptide‐HLA	interactions	and	the	relationship	between	HLA	binding	and	T‐cell	activation.
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terms	of	cellular	phenotype	(CD,	TCR	Vβ,	and	chemokine	receptors	
[flow	 cytometry]),	 secretion	 of	 cytokines	 and	 cytolytic	 molecules	
(ELIspot),	antigen	specificity	(dose‐response	studies	and	cross‐reac‐
tivity	with	 structurally‐related	 compounds	 [3H]thymidine	 uptake]),	
pathways	of	activation	(antigen‐presenting	cell	pulsing	experiments,	
fixation	of	antigen‐presenting	cells	to	block	processing,	and	addition	
of	 glutathione	 to	 block	 drug	metabolite	 protein	 binding),	 and	 the	
involvement	of	HLA‐B*13:01	 in	the	T‐cell	 response	 (HLA	antibody	
blocking	experiments	and	use	of	partly	HLA	matched	antigen‐pre‐
senting	cells).	Detailed	methods	are	available	in	as	Data	S1.
2.4 | Statistics
All	 statistical	 analysis	 (one‐way	 ANOVA	 unless	 stated	 otherwise)	
was	performed	using	SigmaPlot	12	software	(*P	<	0.05).
3  | RESULTS
3.1 | Patch testing and in vitro activation of 
hypersensitive patient PBMC
After	 72‐hour	 drug	 exposure,	 3	 out	 of	 6	 patients	 displayed	 dap‐
sone	concentration‐dependent	positive	readings	(Figure	1A).	PBMC	
from	all	3	patch	test‐positive	patients	were	stimulated	to	proliferate	
strongly	in	the	presence	of	dapsone	and	nitroso	dapsone	(Figure	1B).	
Positive	dapsone‐specific	proliferative	responses	(stimulation	index	
[SI]	 2	 or	 above)	 and/or	 IFN‐γ	 secretion	 were	 also	 detected	 with	
PBMC	from	 the	3	patch	 test‐negative	patients,	while	nitroso	dap‐
sone	responses	were	detected	in	2	patients	(Figure	1B‐D).	Of	note,	
patient	 7	 displayed	 a	 negative	nitroso	dapsone	 lymphocyte	 trans‐
formation	 test	 response	 on	 initial	 testing	 (Figure	 1B)	 and	 a	 weak	
response	 when	 the	 assay	 was	 repeated	 (Figure	 1D).	 PBMC	 were	
not	 activated	 with	 the	 co‐medications	 rifampicin	 and	 clofazimine	
(Figure	1D).	PBMC	from	dapsone‐naïve	 (SI	<	2)	and	dapsone‐toler‐
ant	(Figure	S1)	HLA‐B*13:01+	controls	proliferated	in	the	presence	
of	phytohemagglutinin,	but	not	the	test	drugs.
3.2 | Dapsone and nitroso dapsone activate 
CD4+ and CD8+ clones
A	 total	 of	 1334	 and	 1374	 CD4+	 and	 CD8+	 clones,	 respectively,	
were	expanded	from	dapsone	and	nitroso	dapsone	T‐cell	lines	from	
patients	5,	6,	 and	8;	626	CD4+	 clones	displayed	 reactivity	 against	
dapsone	or	nitroso	dapsone	(Figure	S2).	Dapsone‐	and	nitroso	dap‐
sone‐specific	CD8+	 clones	were	generated	 in	 lower	numbers;	168	
were	activated	with	either	 the	drug	or	drug	metabolite.	Dapsone‐	
and	 nitroso	 dapsone‐responsive	 CD4+	 and	 CD8+	 clones	were	 de‐
tected	in	equal	numbers	(Table	2).
TA B L E  1  Patients’	demographics	and	details	of	the	hypersensitivity	reaction
Patient ID Gender Age (years) Medication history
Onset of 
symptoms (days) Clinical presentation Skin patch test
1 Female 43 Dapsone,	rifampin,	
and	clofazimine
3 Fever,	rash,	and	abnormal	liver	
function	tests
−
3 Female 25 Dapsone,	rifampin,	
and	clofazimine
28 Fever,	rash,	and	abnormal	liver	
function	tests
−
5 Male 39 Dapsone,	rifampin,	
and	clofazimine
30 Fever +
6 Male 41 Dapsone,	rifampin,	
and	clofazimine.
48 Fever,	rash,	and	lymphadenopathy +
7 Male 54 Dapsone,	rifampin,	
and	clofazimine
16 Fever,	rash,	and	abnormal	liver	
function	tests	(AST	47.7	U/L;	
ALP132.3	U/L)
−
8 Female 27 Dapsone,	rifampin,	
and	clofazimine
17 Fever	and	abnormal	liver	function	
tests	(AST	56.3	U/L;	ALP	225.7	
U/L;	GGT	184.8	U/L;	TBIL	
38.8	μmol/L;	DBIL	21.3	μmol/L;	
IBIL	17.5)
+
F I G U R E  1  Diagnosis	of	dapsone	hypersensitivity	by	skin	testing	and	in	vitro	assays.	A,	Skin	patch	test	results	for	dapsone	
hypersensitivity.	Skin	was	exposed	to	dapsone	in	polyethylene	glycol	200	at	dilutions	of	0%,	0.1%,	0.5%,	1%,	5%,	10%,	15%,	2%,	and	25%.	
The	patch	tape	was	left	to	the	skin	for	48	h,	and	diagnosis	was	made	24	h	later.	Red	ovals	show	areas	of	inflamed	skin.	B,	Peripheral	blood	
mononuclear	cells	(PBMC)	from	patients	were	exposed	to	graded	concentrations	of	dapsone	or	nitroso	dapsone.	Proliferation	was	measured	
after	5	d	by	the	addition	of	[3H]thymidine	for	16	h.	Results	are	expressed	as	mean	±	SD	cpm	of	triplicate	cultures.	A	doubling	of	cpm	in	drug‐
treated	cultures	over	vehicle	control	is	considered	positive.	C,	PBMC	from	patients	were	exposed	to	optimal	concentrations	of	dapsone	or	
nitroso	dapsone,	and	IFN‐γ	release	was	visualized	by	ELIspot.	D,	PBMC	from	patients	were	exposed	to	graded	concentrations	of	dapsone,	
nitroso	dapsone,	rifampicin,	and	clofazimine.	Proliferation	was	measured	as	described	in	(B)	(DDS,	dapsone;	DDS‐NO,	nitroso	dapsone;	PHA,	
phytohaemagglutinin)
     |  5ZHAO et Al.
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One	 hundred	 and	 two	 well‐growing	 clones	 were	 selected	
for	 dose‐titration	 studies	 and	 the	 analysis	 of	 cytokine	 secretion.	
Proliferative	 responses	 were	 detected	 with	 3	 well‐tolerated	 con‐
centrations	 of	 dapsone	 (125‐500	µmol/L)	 and	 nitroso	 dapsone	
(5‐20	µmol/L)	and	drug	treatment	resulted	 in	 the	secretion	of	Th1	
(IFNγ),	Th2	(IL‐5,	IL‐13),	and	Th22	(IL‐22)	cytokines,	alongside	the	cy‐
tolytic	molecules	perforin,	granzyme	B,	and	FasL.	CD4+	and	CD8+ 
clones	secreted	similar	 levels	of	cytokines	and	cytolytic	molecules	
(Figure	2).	 Table	 S3	 shows	 the	percentage	of	 dapsone	 (DDS)‐	 and	
nitroso	dapsone	(DDS‐NO)‐responsive	CD4+	and	CD8+	clones	that	
secrete	individual	cytokines.
3.3 | Dapsone‐ and nitroso dapsone‐responsive 
CD4+ and CD8+ clones display three distinct 
patterns of cross‐reactivity
Sixty‐three	 dapsone‐	 and	 98	 nitroso	 dapsone‐responsive	 CD4+ 
and	 CD8+	 clones	 were	 assayed	 for	 cross‐reactivity.	 When	 all	 of	
the	dapsone‐responsive	clones	were	assessed	 together,	 low	 levels	
of	 proliferation	 were	 observed	 with	 nitroso	 dapsone	 (Figure	 3A).	
The	maximum	concentration	of	nitroso	dapsone	used	was	10	times	
lower	than	the	dapsone	concentration.	Analysis	of	individual	clones	
revealed	 three	 distinct	 cross‐reactivity	 patterns:	 dapsone‐spe‐
cific,	and	weakly	and	strongly	cross‐reactive	with	nitroso	dapsone.	
Approximately	90%	of	the	clones	were	dapsone‐specific	or	weakly	
cross‐reactive	(Figure	3B,C).
Nitroso	dapsone	CD4+	and	CD8+	clones	displayed	a	much	higher	
level	of	cross‐reactivity	 (Figure	3A).	However,	3	patterns	of	cross‐
reactivity	were	again	observed	with	individual	clones:	nitroso	dap‐
sone‐specific,	and	weakly	and	strongly	cross‐reactive	with	dapsone.	
In	contrast	to	the	dapsone‐responsive	clones,	approximately	90%	of	
the	nitroso	dapsone‐responsive	 clones	were	nitroso	dapsone‐spe‐
cific	or	highly	cross‐reactive	(Figure	3B,C).
Dapsone‐	 and	 nitroso	 dapsone‐responsive	 clones	 were	 also	
stimulated	 to	 proliferate	 with	 dapsone	 hydroxylamine;	 however,	
proliferative	 responses	were	 not	 detected	when	 clones	were	 cul‐
tured	with	 (a)	dapsone	analogues	with	substitutions	 in	the	sulfone	
group,	 (b)	dapsone	analogues	with	amine	groups	 in	different	posi‐
tions	on	the	aromatic	rings,	and	(c)	structurally	distinct	sulfonamide	
antimicrobials	(Figure	S3).
The	 stability	 of	 nitroso	dapsone	 in	 the	proliferation	 assay	was	
assessed.	Nitroso	dapsone	was	 converted	 rapidly	 to	 azoxy	dimers	
and	the	parent	compound.	Both	compounds	were	detectable	within	
10	minutes.	 After	 2	days,	 50%	 of	 nitroso	 dapsone	 had	 been	 con‐
verted	to	dapsone	(Figure	3D‐E).
3.4 | Cross‐reactive clones are activated 
with equivalent concentrations of dapsone and 
nitroso dapsone
Six	 strong	 and	 weakly	 cross‐reactive	 clones	 were	 incubated	 with	
dapsone	and	nitroso	dapsone	at	concentrations	of	0.1‐100	µmol/L	
to	define	the	minimum	stimulatory	concentrations	of	the	two	com‐
pounds.	 Clones	 were	 stimulated	 to	 proliferate	 with	 equivalent	
concentrations	 of	 each	 compound	 irrespective	 of	 the	 extent	 of	
cross‐reactivity	(Figure	4).
3.5 | Dapsone‐ and nitroso dapsone‐responsive 
CD4+ and CD8+ clones expressing multiple TCR Vβ 
chains display distinct chemokine receptor profiles
Dapsone‐	and	nitroso	dapsone‐responsive	CD4+	and	CD8+	clones	
expressed	single,	but	variable	TCR	Vβ	chains	(Figure	S4A),	with	no	
clear	 differences	 discernible	when	 CD4+	 and	 CD8+	 or	 dapsone‐	
and	nitroso	dapsone‐responsive	clones	were	compared.	Dapsone‐	
and	 nitroso	 dapsone‐responsive	 CD4+	 clones	 expressed	 high	
Phenotype and drug 
specificity
Total number of 
clones
Number of drug‐spe‐
cific clones
Percentage of 
responding clones (%)
Patient	8
CD4+,	DDS+ 236 176 74.58
CD8+,	DDS+ 245 29 11.84
CD4+,	DDS‐NO+ 384 210 54.69
CD8+,	DDS‐NO+ 304 54 17.76
Patient	6
CD4+,	DDS+ 177 76 42.94
CD8+,	DDS+ 178 14 7.87
CD4+,	DDS‐NO+ 208 57 27.40
CD8+,	DDS‐NO+ 285 15 5.26
Patient	5
CD4+,	DDS+ 180 64 35.56
CD8+,	DDS+ 170 36 21.18
CD4+,	DDS‐NO+ 149 43 28.86
CD8+,	DDS‐NO+ 192 20 10.42
TA B L E  2  Phenotype	and	drug	
specificity	of	T‐cell	clones	generated	from	
dapsone	hypersensitive	patients
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F I G U R E  2  Proliferative	response	and	cytokine	release	by	dapsone‐	and	nitroso	dapsone‐responsive	CD4+	and	CD8+	clones.	A,	One	
hundred	and	two	CD4+	or	CD8+	clones	were	incubated	with	autologous	antigen‐presenting	cells	and	either	dapsone	(125‐500	µmol/L)	
or	nitroso	dapsone	(5‐20	µmol/L)	in	triplicate	cultures	for	48	h.	Proliferative	responses	were	measured	by	the	addition	of	[3H]thymidine.	
Results	are	expressed	as	mean	±	SD	cpm	of	the	indicated	number	of	clones.	B,	Detection	of	IFN‐γ,	IL‐5,	IL‐13,	IL‐17,	IL‐22,	granzyme	
B,	perforin,	and	Fas‐ligand	secretion	by	dapsone‐	and	nitroso	dapsone‐responsive	CD4+	and	CD8+	clones.	Clones	were	incubated	
with	autologous	antigen‐presenting	cells,	and	either	dapsone	or	nitroso	dapsone	and	cytokine	release	was	visualized	by	ELIspot.	C,	
Representative	ELIspot	images	showing	the	cytokines	released	by	dapsone	and	nitroso	dapsone‐responsive	CD8+	clones
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levels	 of	 the	 chemokine	 receptors	 CXCR3	 and	CCR4.	 The	 CD8+ 
clones	expressed	CXCR3	and	CCR4	alongside	CCR10,	CCR9,	and	
CCR6	(Figure	S4B).
3.6 | HLA‐restricted activation of dapsone‐ and 
nitroso dapsone‐responsive clones ensues via 
different mechanisms
Stimulation	 of	 dapsone‐	 and	 nitroso	 dapsone‐responsive	 CD4+ and 
CD8+	 clones	 was	 dependent	 on	 the	 presence	 of	 antigen‐present‐
ing	 cells	 (Figure	5A).	Use	of	blocking	antibodies	 revealed	 that	CD4+ 
and	 CD8+	 proliferative	 responses	 to	 dapsone	 and	 nitroso	 dapsone	
were	HLA	class	 II	 and	 I	 restricted,	 respectively	 (Figure	5B).	Fixation	
of	antigen‐presenting	cells	with	glutaraldehyde	had	no	effect	on	the	
activation	of	CD4+	or	CD8+	clones	with	dapsone.	In	contrast,	antigen‐
presenting	 cell	 fixation	 reduced	 the	 extent	 of	 proliferation	with	 the	
nitroso	metabolite	 (Figure	6A).	The	 residual	 response	detected	with	
nitroso	dapsone	and	fixed	antigen‐presenting	cells	relates	to	the	con‐
version	of	nitroso	dapsone	to	dapsone	in	culture.
Nitroso	 dapsone‐responsive	 CD8+	 clones	 were	 activated	 with	
antigen‐presenting	cells	pulsed	with	nitroso	dapsone	for	0.5‐2	hours	
(Figure	6B).	Two	out	of	4	nitroso	dapsone‐responsive	CD4+	clones	
were	also	stimulated	to	proliferate	with	nitroso	dapsone‐pulsed	an‐
tigen‐presenting	cells.	Antigen‐presenting	cells	pulsed	with	dapsone	
for	 0.5‐2	hours	 did	 not	 activate	 the	 dapsone‐responsive	 CD4+ or 
CD8+	clones.
Figure	 S5A	 compares	 the	 level	 of	 nitroso	 dapsone	 glutathi‐
one	adducts	formed	in	the	cell	culture	assay	in	the	presence	and	
F I G U R E  3  Cross‐reactivity	of	dapsone‐	and	nitroso	dapsone‐responsive	T‐cell	clones.	Dapsone‐	and	nitroso	dapsone‐responsive	
CD4+ and	CD8+	clones	were	cultured	with	irradiated	autologous	EBV‐transformed	B	cells	and	either	dapsone	(100‐500	µmol/L)	or	the	
nitroso	metabolite	(5‐20	µmol/L)	in	triplicate	cultures	for	48	h.	T‐cell	proliferative	responses	were	assessed	through	the	addition	of	[3H]‐
thymidine.	A,	Mean	cross‐reactivity	data	for	153	clones	divided	according	to	the	drug	antigen	peripheral	blood	mononuclear	cells	were	
cultured	with	to	generate	clones	and	CD	phenotype.	B,	Pie	charts	showing	number	of	clones	with	a	particular	cross‐reactivity	profile	
(compound	specific,	weekly	cross‐reactive	(cross‐reactive	compound	displaying	10%‐50%	response	detected	with	comparator)	and	strongly	
cross‐reactive	(cross‐reactive	compound	displaying	>	50%	response	detected	with	comparator).	C,	Representative	clones	displaying	each	
response	profile.	D,	Relative	quantification	of	dapsone	and	azoxy	dimer	in	cultures	containing	nitroso	dapsone	(30	µmol/L),	autologous	
EBV‐transformed	B	cells,	and	T‐cell	clones.	E,	Absolute	quantification	of	dapsone	formation	in	cultures	containing	nitroso	dapsone	
(30	µmol/L),	autologous	EBV‐transformed	B	cells,	and	T‐cell	clones.	Left	hand	graph	shows	the	standard	curve	for	dapsone	(concentration	
range:	5	nmol/L‐1	µmol/L).	Right	hand	side	graph	shows	the	time‐dependent	formation	of	dapsone
F I G U R E  4  Dapsone	and	nitroso	dapsone	activate	T‐cell	clones	at	the	same	minimum	concentration.	A,	Dapsone‐	and	(B)	nitroso	
dapsone‐responsive	CD4+	and	CD8+	clones	were	cultured	with	irradiated	autologous	EBV‐transformed	B	cells	and	either	dapsone	
(0.1‐100	µmol/L)	or	the	nitroso	metabolite	(0.1‐100	µmol/L)	in	triplicate	cultures	for	48	h.	T‐cell	proliferative	responses	were	assessed	
through	the	addition	of	[3H]‐thymidine.	Representative	weakly	and	strongly	cross‐reactive	dapsone	and	nitroso	dapsone‐responsive	clones	
are	shown
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absence	 of	 exogenous	 glutathione.23,24	 Adducts	 were	 formed	
rapidly	 (within	 2	hours),	 and	 the	 level	 of	 adduct	 formation	was	
several	orders	of	magnitude	higher	in	the	presence	of	exogenous	
glutathione.	Figure	S6	contains	traces	showing	how	the	adducts	
were	quantified.	The	addition	of	glutathione	 to	 the	T‐cell	assay	
containing	soluble	nitroso	dapsone	reduced	the	strength	of	 the	
proliferative	 response,	 while	 the	 response	 to	 nitroso	 dapsone‐
pulsed	 antigen‐presenting	 cells	was	 completely	 blocked	 (Figure	
S5B).
3.7 | Dapsone and nitroso dapsone bind with a 
degree of selectively to HLA‐B*13:01 to activate 
certain CD8+ T‐cell clones
EBV‐transformed	 B	 cells	 were	 generated	 from	 9	 healthy	 do‐
nors	 expressing	 HLA	 alleles	 with	 >90%	 sequence	 homology	 to	
HLA‐B*13:01.	HLA	typing	of	the	healthy	donors	 is	shown	in	Table	
S2.	 The	 B‐cell	 lines	 were	 used	 to	 explore	 the	 requirement	 for	
HLA‐B*13:01	in	dapsone‐	and	nitroso	dapsone‐specific	CD8+	T‐cell	
F I G U R E  5  Antigen‐presenting	
cells	are	required	for	the	activation	of	
dapsone‐	and	nitroso	dapsone‐responsive	
CD4+	and	CD8+	clones.	A,	Dapsone‐	and	
nitroso	dapsone‐responsive	CD4+ and 
CD8+	clones	were	cultured	with	dapsone	
(500	µmol/L)	or	the	nitroso	metabolite	
(20	µmol/L)	in	triplicate	cultures	for	48	h	
either	in	the	presence	or	absence	of	
autologous	EBV‐transformed	B	cells.	B,	
Dapsone‐	and	nitroso	dapsone‐responsive	
CD4+	and	CD8+	clones	were	cultured	
with	antigen‐presenting	cells	and	dapsone	
(500	µmol/L)	or	the	nitroso	metabolite	
(20	µmol/L)	in	triplicate	cultures	for	48	h	
either	in	the	presence	or	absence	of	anti‐
HLA	class	I	and	II	blocking	antibodies.	
[3H]‐thymidine	was	added	for	16	h	to	
measure	drug‐specific	proliferative	
responses
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F I G U R E  6  Dapsone	and	nitroso	dapsone	activate	T	cells	via	different	pathways.	A,	Dapsone‐	and	nitroso	dapsone‐responsive	CD4+ and 
CD8+	clones	were	cultured	with	dapsone	or	the	nitroso	metabolite	in	the	presence	of	either	irradiated	or	glutaraldehyde‐fixed	autologous	
EBV‐transformed	B	cells	(APC,	antigen‐presenting	cells)	in	triplicate	cultures	for	48	h.	Fixation	blocks	antigen	processing.	B,	Dapsone‐	and	
nitroso	dapsone‐responsive	CD4+	and	CD8+	clones	were	cultured	with	drug‐	or	drug	metabolite‐pulsed	(0.5‐2	h)	irradiated	autologous	EBV‐
transformed	B	cells	in	the	absence	of	soluble	drug	in	triplicate	cultures	for	48	h.	T‐cell	proliferative	responses	were	assessed	through	the	
addition	of	[3H]‐thymidine
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activation.	Autologous	antigen‐presenting	cells	and	antigen	present‐
ing	from	1	additional	patients	were	used	as	comparators.
As	has	 been	described	previously	 for	 other	 drugs,25,26	 30%	of	
dapsone	and	nitroso	dapsone‐responsive	HLA	class	I	restricted	CD8	
clones	displayed	proliferative	responses	with	the	drug	or	metabolite	
and	antigen‐presenting	cells	expressing	a	wide	variety	of	HLA	alleles	
(results	not	 shown).	Other	clones	were	activated	with	 the	drug	or	
metabolite	 only	 in	 the	 presence	 of	 autologous	 antigen‐presenting	
cells.	Despite	this,	30%‐40%	of	CD8+	clones	displayed	a	degree	of	
HLA‐B*13:01	allele	restriction.	Figure	7A,B	shows	3	clones	(1	dap‐
sone‐	 and	 2	 nitroso	 dapsone‐responsive)	 that	 were	 stimulated	 to	
proliferate	 exclusively	 in	 the	presence	of	 dapsone	or	 nitroso	dap‐
sone	 and	 antigen‐presenting	 cells	 expressing	HLA‐B*13:01.	 Three	
additional	 clones	 (1	 dapsone‐	 and	 2	 nitroso	 dapsone‐responsive)	
are	shown	that	were	activated	in	the	presence	of	antigen‐present‐
ing	 cells	 expressing	HLA‐B*13:01	 and	either	B*13:02,	B*58:01,	 or	
B*51:01.
The	2	dapsone‐responsive	CD8+	clones	were	expanded	in	suffi‐
cient	numbers	for	us	to	conduct	a	proliferation	assay	using	antigen‐
presenting	cells	from	the	6	hypersensitive	patients	that	all	express	
HLA‐B*13:01.	The	clones	were	activated	in	the	presence	of	dapsone	
and	antigen‐presenting	cells	from	all	of	the	patients	(Figure	7C).
4  | DISCUSSION
Knowledge	of	 the	role	drug	metabolism	plays	 in	the	generation	of	
antigenic	determinants	that	activate	T	cells	is	limited.	Circumstantial	
evidence	supporting	a	role	for	drug	metabolism	includes	the	identi‐
fication	of	protein‐reactive	metabolites	 for	many	drugs	associated	
with	a	high	 incidence	of	hypersensitivity	and	the	 induction	of	tox‐
icity	 in	target	tissue	by	reactive	metabolites	and	hence	the	poten‐
tial	 to	 disrupt	 immune	 regulatory	 pathways	 through	 the	 provision	
of	danger	signals.27	However,	the	most	direct	evidence	linking	drug	
metabolism	to	the	development	of	hypersensitivity	is	the	detection	
of	halothane‐specific	antibodies	 in	patients	with	 liver	failure28 and 
the	 observation	 that	 halothane	 protein	 adducts	 activate	 T	 cells.29 
Furthermore,	halothane	derivatives	that	form	lower	 levels	of	reac‐
tive	metabolite	are	associated	with	a	decreased	risk	of	liver	injury.30 
To	 explore	whether	metabolites	 activate	 hypersensitive	 patient	 T	
F I G U R E  7  Dapsone	and	nitroso	dapsone	bind	with	a	degree	of	selectively	to	HLA‐B*13:01	to	activate	certain	CD8+	T‐cell	clones.	A,	
Nitroso	dapsone‐	and	(B)	dapsone‐responsive	CD8+	clones	were	cultured	with	drug	or	drug	metabolite	and	irradiated	EBV‐transformed	B	
cells	(APC,	antigen‐presenting	cells)	from	10	donors	expressing	different	HLA‐B	alleles	in	triplicate	cultures	for	48	h.	The	complete	HLA	
type	of	the	different	donors	is	shown	in	Table	S2.	C,	Dapsone‐responsive	CD8+	clones	were	cultured	with	dapsone	and	irradiated	EBV‐
transformed	B	cells	from	6	hypersensitive	patients	expressing	HLA‐B*13:01	in	triplicate	cultures	for	48	h.	T‐cell	proliferative	responses	were	
assessed	through	the	addition	of	[3H]‐thymidine
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cells	in	vitro, co‐culture	strategies	have	been	developed	using	micro‐
somal	 metabolite	 generating	 systems.31,32	 Enhanced	 drug‐specific	
T‐cell	responses	have	been	reported	with	drugs	in	the	presence	of	
a	metabolizing	system;	however,	it	is	very	difficult	to	delineate	the	
disparate	effects	of	the	parent	drug	and	metabolites.	For	this	rea‐
son,	we	synthesized	the	reactive	metabolite	of	sulfamethoxazole,33 
which	causes	immune‐mediated	skin	and	liver	reactions	that	are	not	
linked	 to	 expression	 of	 a	 specific	 HLA	 allele.34,35	Working	 along‐
side	other	researchers	 in	the	field	we	have	shown	that	PBMC	and	
inflamed	tissue	from	all	hypersensitive	patients	contain	T	cells	that	
are	activated	with	sulfamethoxazole	and/or	 its	reactive	metabolite	
via	different	pathways	(ie,	direct	HLA	binding	and	a	hapten	pathway,	
respectively).12,13
In	recent	years,	researchers	studying	hypersensitivity	reactions	
strongly	linked	to	expression	of	specific	HLA	alleles	have	focussed	
exclusively	 on	 the	 interaction	 between	 parent	 drug	 and	 the	 HLA	
molecule.	This	is	because	the	parent	drug	is,	for	the	most	part,	the	
only	reagent	available	for	in	vitro	cell	culture	studies.	The	observa‐
tion	 that	T	cells	 from	patients	with	hypersensitivity	 to	drugs	 such	
as	carbamazepine	are	activated	with	the	parent	drug11	has	lead	re‐
searchers	to	hypothesize	that	reactive	metabolites	are	not	involved	
in	the	development	of	HLA	allele‐restricted	forms	of	drug	hypersen‐
sitivity.	To	investigate	this	hypothesis,	we	now	focused	on	dapsone	
hypersensitivity	in	patients	with	leprosy.	Dapsone	is	a	model	study	
drug	 as	 hypersensitivity	 reactions	 in	 patients	 are	 strongly	 linked	
to	 the	expression	of	HLA‐B*13:01,19	 the	 reactive	nitroso	metabo‐
lite	of	dapsone	has	been	synthesized	in	a	stable	form,15 and patient 
samples	are	available	for	mechanistic	studies.	Utilizing	PBMC	from	
HLA‐B*13:01+	patients,	we	show	CD4+	and	CD8+	T‐cell	responses	
to	dapsone	and	the	nitroso	metabolite.	Furthermore,	dapsone	and	
nitroso	dapsone	bind	to	HLA‐B*13:01	to	selectively	activate	certain	
CD8+	clones.
Six	 HLA‐B*13:01+	 patients	 that	 developed	 hypersensitivity	
while	 receiving	 dapsone	 in	 combination	 with	 rifampicin	 and	 clo‐
fazimine	 were	 recruited	 to	 the	 study.	 Three	 displayed	 a	 positive	
patch	 test	 response	 to	 dapsone.	 PBMC	 from	 all	 six	 patients	were	
stimulated	to	proliferate	and/or	secrete	IFN‐γ	after	stimulation	with	
dapsone	or	the	nitroso	metabolite.	The	strongest	in	vitro	responses	
were	 seen	 in	 the	 patients	 with	 the	 positive	 patch	 test	 response,	
and	these	patients	were	selected	for	serial	dilution	experiments	to	
search	for	drug‐	and	drug	metabolite‐responsive	T‐cell	clones.	CD4+ 
and	CD8+	 subpopulations	were	purified	before	plating	 single	 cells	
in	 culture	 plates	 for	 the	 cloning	 procedure.	Dapsone‐	 and	 nitroso	
dapsone‐responsive	T	cells	were	generated	in	almost	equal	numbers	
(dapsone	395;	nitroso	dapsone	399).	The	ratio	of	dapsone‐	or	nitroso	
dapsone‐responsive	CD4+	and	CD8+	T‐cell	clones	was	4‐5:1	 in	pa‐
tients	6	and	8	and	2:1	 in	patient	5,	which	demonstrates	 that	drug	
exposure	consistently	results	 in	CD4+	and	CD8+	responses	against	
the	drug	antigens.	This	is	in	stark	contrast	to	the	findings	with	abaca‐
vir	where	CD8+	T	cells	are	the	only	cells	activated	with	the	drug.36,37 
The	activation	of	CD4+	and	CD8+	clones	that	expressed	an	array	of	
TCR	Vβ	receptors,	with	dapsone	or	nitroso	dapsone,	was	HLA	class	
II	and	class	I	restricted,	respectively.	This	confirms	our	previous	data	
with	PBMC	from	healthy	donors,15	which	shows	that	both	dapsone	
and	nitroso	dapsone	interact	with	HLA	class	I	and	class	II	molecules.
The	availability	of	cloned	CD4+	and	CD8+	T	cells	permitted	the	
detailed	analysis	of	cross‐reactivity	between	dapsone,	nitroso	dap‐
sone	and	structurally	related	compounds,	mechanisms	of	dapsone‐	
and	nitroso	dapsone‐specific	T‐cell	activation,	and	the	involvement	
of	the	allele	HLA‐B*13:01	in	antigen	presentation.	Cross‐reactivity	
studies	revealed	that	the	position	of	the	amine	groups	on	the	aro‐
matic	rings	of	dapsone	and	the	availability	of	the	sulfone	group	was	
critical	for	the	activation	of	the	T‐cell	clones.	Furthermore,	as	a	panel	
of	sulfonamides	that	contain	one	aromatic	amine	group	did	not	ac‐
tivate	the	clones,	both	of	dapsones’	aromatic	amines	were	required	
for	T‐cell	activation.
25%‐50%	of	 CD4+	 and	CD8+	 clones	were	 classified	 as	 highly	
specific	as	they	were	only	activated	with	one	compound	(either	the	
parent	drug	or	metabolite	 [Figure	3B]).	This	 confirms	 that	T	cells	
recognize	and	respond	selectively	to	the	two	different	forms	of	the	
dapsone	antigen.	Dapsone	has	an	unusual	structure	in	that	the	two	
aromatic	 amines	 connected	 to	 the	 sulfone	 group	 are	 identical.	 If	
the	structure	of	a	nitroso	dapsone‐modified	HLA	binding	peptide	is	
compared	with	dapsone	complexed	to	the	same	peptide,	it	is	likely	
that	similar	conformations	will	be	observed,	and	as	such,	the	inter‐
action	with	the	T‐cell	receptor	will	be	the	same.	Thus,	our	working	
hypothesis	to	explain	the	drug‐	or	drug	metabolite‐specific	activa‐
tion	of	certain	clones	is	that	the	HLA	binding	peptides	also	partici‐
pate	in	the	TCR	interaction	and	impart	a	degree	of	selectivity.
When	 using	 optimum	 concentrations	 of	 dapsone	
(100‐500	µmol/L)	 and	 nitroso	 dapsone	 (5‐20	µmol/L)	 to	 activate	
CD4+	 and	CD8+	T	 cells,	 clones	displaying	high	 (ie,	 at	 least	50%	of	
the	 response	 detected	with	 the	 opposite	 compound)	 and	 low	 (ie,	
10%‐50%	of	 the	 response	detected	with	 the	opposite	 compound)	
levels	of	cross‐reactivity	were	also	detected.	The	majority	of	dap‐
sone‐responsive,	 cross‐reactive	 CD4+	 and	 CD8+	 clones	 displayed	
low	 levels	 of	 cross‐reactivity	 with	 nitroso	 dapsone.	 Using	 quanti‐
tative	 mass	 spectrometry,	 we	 were	 able	 to	 demonstrate	 that	 the	
nitroso	metabolite	is	reduced	to	dapsone	in	the	2‐day	proliferation	
assay.	Thus,	clones	incubated	with	30	µmol/L	nitroso	dapsone	were	
exposed	 to	 2.5‐15	µmol/L	 of	 the	 parent	 drug,	 which	 stimulates	 a	
suboptimal	T‐cell	proliferative	response.	In	contrast,	the	majority	of	
cross‐reactive	 nitroso	 dapsone‐responsive	CD4+	 and	CD8+	 clones	
displayed	high	levels	of	cross‐reactivity	with	100‐500	µmol/L	dap‐
sone.	To	investigate	the	response	profiles	further,	a	panel	of	cross‐
reactive	 dapsone‐	 and	 nitroso	 dapsone‐responsive	 clones	 were	
cultured	with	equal	concentrations	of	the	parent	drug	and	metabo‐
lite	(0.1‐100	µmol/L).	Interestingly,	weakly	and	strongly	cross‐reac‐
tive	clones	were	activated	with	the	same	concentrations	of	dapsone	
and	nitroso	dapsone	with	similar	dose‐response	curves	until	nitroso	
metabolite‐induced	toxicity	was	detected.	These	data	are	in	contrast	
to	our	earlier	studies	with	sulfamethoxazole	and	its	nitroso	metab‐
olite,	where	the	parent	drug	activates	T	cells	at	significantly	higher	
concentrations.13	It	is	reasonable	to	assume	that	HLA	binding	pep‐
tides	 play	 a	 less	 important	 role	 in	 the	 triggering	 of	 cross‐reactive	
TCR.
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Given	that	clones	displaying	reactivity	toward	dapsone	and/or	
the	nitroso	metabolite	were	detected,	it	was	important	to	define	
mechanisms	 of	 antigen	 presentation	 including	 the	 requirement	
for	antigen	processing.	Antigen‐presenting	cells	were	required	for	
the	strong	activation	of	CD4+	and	CD8+	clones	with	dapsone	and	
the	nitroso	metabolite.	Clones	were	activated	with	dapsone	in	the	
presence	of	irradiated	and	glutaraldehyde‐fixed	antigen‐present‐
ing	cells.	In	contrast,	fixation	reduced	the	strength	of	the	nitroso	
dapsone‐specific	T‐cell	proliferative	response.	This	suggests	that	
dapsone	activates	T	 cells	 through	a	direct	 interaction	with	HLA	
molecules,	whereas	nitroso	dapsone	binds	 covalently	 to	 cellular	
protein	forming	adducts	that	require	processing	to	generate	anti‐
genic	peptides.	As	discussed	above,	the	best	explanation	for	the	
weak	response	of	nitroso	dapsone‐responsive	clones	with	soluble	
nitroso	dapsone	and	fixed	antigen‐presenting	cells	 is	 the	forma‐
tion	of	 dapsone	 in	 the	proliferation	 assay.	 The	drug‐specific	 ac‐
tivation	 of	 clones	 from	dapsone	 hypersensitive	 patients	 by	 two	
pathways	 has	 important	 implications	 for	 the	 future	 structural	
analysis	of	how	dapsone	and	nitroso	dapsone	interacts	with	HLA	
molecules.	 Application	 of	 drug‐	 or	 drug	metabolite‐pulsed	 anti‐
gen‐presenting	cells	 instead	of	soluble	drug	 in	T‐cell	assays	pro‐
vides	a	tool	to	differentiate	between	the	effects	of	covalent	and	
non‐covalent	forms	of	drug.14,39	Dapsone‐responsive	clones	were	
not	 activated	 with	 dapsone‐pulsed	 antigen‐presenting	 cells.	 In	
contrast,	6	out	of	the	8	nitroso	dapsone‐responsive	clones	tested	
were	 activated	 with	 nitroso	 dapsone‐pulsed	 antigen‐presenting	
cells	and	 the	strength	of	 the	 induced	response	was	 the	same	as	
that	 seen	with	 the	parent	 drug.	 Two	of	 the	nitroso	dapsone‐re‐
sponsive	clones	were	not	activated	with	pulsed	antigen‐present‐
ing	cells;	interestingly,	both	of	these	clones	cross‐reacted	strongly	
with	dapsone.
Glutathione	is	a	tripeptide	intracellular	antioxidant	that	protects	
cells	 from	exposure	to	aromatic	nitroso	compounds	by	acting	as	a	
reducing	agent	and	through	direct	conjugation.23,24	The	addition	of	
glutathione	to	T‐cell	assays	prevents	the	covalent	binding	of	nitroso	
compounds,	and	hence,	it	is	possible	to	explore	whether	T	cells	are	
activated	with	drug	metabolite‐modified	protein	adducts.40	Nitroso	
dapsone	glutathione	adducts	were	formed	rapidly	 in	cultures	con‐
taining	the	drug	metabolite,	T	cells,	antigen‐presenting	cells,	and	glu‐
tathione.	Moreover,	 glutathione	decreased	 the	 response	of	 clones	
to	soluble	nitroso	dapsone	and	blocked	the	response	to	nitroso	dap‐
sone‐pulsed	antigen‐presenting	cells.	Thus,	the	formation	of	a	cova‐
lent	adduct	between	nitroso	dapsone	and	cellular	proteins	is	needed	
for	the	activation	of	certain	clones.
In	 the	 next	 section	 of	 the	 project,	 antigen‐presenting	 cells	
were	 generated	 from	 healthy	 donors	 expressing	 HLA‐B	 alleles	
with	at	least	90%	sequence	homology	to	HLA‐B*13:01	(including	
an	additional	HLA‐B*13:01+	donor)	to	investigate	whether	either	
dapsone	or	nitroso	dapsone	 interact	with	a	degree	of	selectivity	
to	the	risk	allele	to	activate	CD8+	clones.	As	described	previously	
with	other	forms	of	drug	hypersensitivity,	several	clones	displayed	
HLA	allele‐unrestricted	drug	recognition	(ie,	dapsone	and	nitroso	
dapsone	 stimulated	 a	 proliferative	 response	 in	 the	 presence	 of	
multiple	 antigen‐presenting	 cells	 expressing	 different	HLA‐B	 al‐
leles).25	Other	 clones	were	only	 activated	 in	 the	presence	of	ni‐
troso	dapsone	and	autologous	antigen‐presenting	cells.	However,	
a	 panel	 of	 clones	 were	 selectively	 activated	 with	 dapsone	 or	
nitroso	 dapsone	 in	 the	 presence	 of	 antigen‐presenting	 cells	 dis‐
playing	HLA‐B*13:01.	 Cross‐reactivity	was	 observed	 for	 several	
of	these	clones;	however,	no	predominant	TCR	Vβ	receptors	were	
expressed.	This	 indicates	that	both	the	parent	drug	and	reactive	
metabolite	 interacts	with	HLA‐B*13:01	 to	activate	certain	CD8+ 
clones.	We	are	therefore	synthesizing	designer	nitroso	dapsone‐
modified	 HLA‐B*13:01	 binding	 peptides	 and	 conducting	 struc‐
tural	analyses	to	compare	the	binding	interaction	of	dapsone	and	
nitroso	dapsone	with	HLA‐B*13:01.
Different	 forms	 of	 drug	 hypersensitivity	 reaction	 are	 asso‐
ciated	with	 the	 secretion	of	 a	 diverse	panel	 of	 cytokines	 from	T	
cells.41	Thus,	ELIspot	was	used	to	profile	cytokine	secretion	from	
dapsone‐	and	nitroso	dapsone‐stimulated	clones.	CD4+	and	CD8+ 
clones	 secreted	 the	 same	 panel	 of	 cytokines	 when	 stimulated	
with	dapsone	or	nitroso	dapsone,	but	expressed	distinct	chemo‐
kine	 receptors.	 Clones	 secreted	 Th1,	 Th2,	 and	 Th22	 cytokines	
alongside	the	cytolytic	molecules	perforin,	granzyme	B,	and	FasL;	
however,	IL‐17	was	not	detected.	IL‐22	secretion	in	the	absence	of	
IL‐17	seems	to	be	a	common	feature	of	drug‐specific	clones	as	this	
profile	 has	 now	 been	 detected	with	 dapsone,	 sulfamethoxazole,	
and piperacillin.42,43	 It	 is	 possible	 that	 this	 profile	 relates	 to	 the	
long‐term	 in	 vitro	 culture	 of	 clones;	 thus,	 a	 future	 study	 explor‐
ing	the	cytokine	profile	in	affected	tissues	would	be	appropriate.	
The	 chemokine	 receptors	 displayed	on	dapsone‐	 or	 nitroso	dap‐
sone‐responsive	CD4+	clones	were	restricted	to	CXCR3	and	CCR4.	
In	 contrast,	 CD8+	 clones	 also	 expressed	 CCR6,	 9,	 and	 10.	 CCR4	
and	CCR10	have	been	 implicated	 in	 the	migration	of	T	 cells	 into	
skin44;	thus,	a	more	detailed	investigation	of	migratory	properties	
of	CD4+	and	CD8+	T	cells	in	patients	with	dapsone	hypersensitivity	
is	warranted.
In	conclusion,	our	study	shows	that	dapsone‐	and	nitroso	dap‐
sone‐responsive	CD4+	and	CD8+	T	cells	circulate	in	hypersensitive	
patients.	T	cells	were	activated	selectively	with	the	parent	drug	and	
drug	metabolite	via	direct	HLA	binding	and	a	hapten	mechanism,	re‐
spectively.	The	detection	of	HLA‐B*13:01‐restricted	dapsone‐	and	
nitroso	dapsone‐responsive	CD8+	clones	indicates	that	dapsone	hy‐
persensitivity	should	be	used	as	an	exemplar	to	explore	the	struc‐
tural	features	of	drug	HLA	binding	and	how	this	interaction	results	
in	a	pathogenic	T‐cell	response.	For	patients	with	suspected	hyper‐
sensitivity,	it	is	critical	to	identify	the	agent	that	caused	the	reaction.	
We	 are	 currently	 exploring	whether	 drug‐peptide	 antigens	 repre‐
sent	effective	reagents	for	T‐cell	activation.	A	better	understanding	
of	drug	antigenicity	will	 lead	to	the	development	of	 improved	evi‐
dence‐based	diagnostic	tools.
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